Insider buying · SEC Form 4

Insider Buying — Jul 30, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

2insider buys
$20.0Mbought in total
1company
0by CEOs, CFOs and other chiefs
SCTXlargest: $15.0M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
SCTXScribe Therapeutics Inc.Carl L. GordonDirector$15.0M1,000,000$15.00New stakeJul 29, 2026
Form 4 ↗
IPO purchase at $15.00/share; SCTX now $18.36 (+22.4% since buy). Gordon is a Partner at OrbiMed Advisors; companion Form 4 also filed by OrbiMed Advisors LLC (accession 0000947871-26-000733) for the same transaction. Part of a $56M+ cluster buy at the SCTX IPO alongside Avoro/Aghazadeh ($36M, filed July 28) and Andreessen Horowitz ($5M).
SCTXScribe Therapeutics Inc.Marc L. Andreessen10% Owner / Venture Investor (Andreessen Horowitz)$5.00M333,333$15.00New stakeJul 29, 2026
Form 4 ↗
IPO purchase at $15.00/share via AH Bio Fund II, L.P.; filing also names Ben Horowitz. SCTX now $18.36 (+22.4% since buy). a16z also received 2,749,392 shares from preferred-stock conversions (AH Bio Funds II & III). Stock ran to $22.31 on first trading day before pulling back to $18.36.

AIThe day in insider buying

SEC Form 4 Insider Scan — July 30, 2026

Scanned the last 24 hours of EDGAR Form 4 filings (151+ Form 4s reviewed, filed July 29–30, 2026). 2 qualifying buys (≥ $250K, transaction type P) totalling $20.0M — both concentrated in Scribe Therapeutics (SCTX), which completed its IPO on July 27, 2026 at $15/share. A third leg of the cluster, Avoro Capital / Behzad Aghazadeh, filed one day earlier (July 28) for $36.1M in combined SCTX purchases and is included in notes for completeness.

Headline filings

  • SCTX — Carl L. Gordon (Director / OrbiMed) bought 1,000,000 shares ≈ $15.0M at $15.00 avg (IPO price); now $18.36 (+22.4% since buy). (filing)
  • SCTX — Marc L. Andreessen & Ben Horowitz / AH Bio Fund II (Andreessen Horowitz) bought 333,333 shares ≈ $5.0M at $15.00 avg (IPO price); now $18.36 (+22.4% since buy). (filing)

Notes

Scribe Therapeutics IPO cluster buy — the dominant story of July 29–30. SCTX is a CRISPR base-editing company that priced its IPO at $15/share on July 23–24 and began trading July 27. The stock immediately ran to $22.31 on first-day enthusiasm before pulling back to $18.36 (still +22% vs. IPO price; volume is very thin at 103 shares today — freshly listed).

Three major biotech-focused institutional investors filed Form 4s within 48 hours of the IPO:

  1. Avoro Capital / Behzad Aghazadeh (filed July 28, just outside our 24h window): 2,333,333 shares at $15.00 in the IPO ($35.0M) + 50,000 shares on the open market at $22.31 ($1.1M) + 7,905 shares at $18.25 on July 28 ($144K) — $36.2M combined.
  2. OrbiMed Advisors / Carl L. Gordon, Director (filed July 29): 1,000,000 shares at $15.00 = $15.0M.
  3. Andreessen Horowitz / AH Bio Fund II (filed July 29): 333,333 shares at $15.00 = $5.0M.

Combined across all three: ≈$56M committed to SCTX at or near IPO pricing, signaling exceptional conviction from elite biotech and tech investors. Jennifer Doudna (Nobel laureate, CRISPR co-inventor) holds ~603K shares via preferred-stock conversion and is listed as a 10% Owner, adding scientific credibility.

Broader universe check: All other notable July 29 insiders in the 151+ filings reviewed were 10b5-1 plan sellers, RSU tax-withholding filers, or option exercisers. No other open-market P-coded purchases ≥ $250K were found outside the SCTX cluster on July 29–30.

Sectors: Biotech / Gene Editing (IPO cluster). No industrial, financial, or energy insider buys qualified today.

Most-bought stocks, last 30 days

  • AVO $60.1M · 8 buysMission Produce, Inc.
  • SCTX $56.3M · 3 buys, 3 insidersScribe Therapeutics Inc.
  • COE $30.0M · 4 buys, 2 insiders51Talk Online Education Group
  • PBLS $16.9M · 2 buys, 2 insidersParabilis Medicines, Inc.
  • FLUT $11.8M · 1 buyFlutter Entertainment plc
  • NTSK $7.53M · 2 buys, 2 insidersNetskope Inc.
  • HDSN $6.49M · 3 buys, 2 insidersHudson Technologies, Inc.
  • NVCT $4.66M · 8 buys, 2 insidersNuvectis Pharma, Inc.
  • GLOO $3.50M · 1 buyGloo Holdings, Inc.
  • ARTV $2.58M · 1 buyArtiva Biotherapeutics, Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • CLBK $2.13M · 5 buys, 5 insidersColumbia Financial, Inc.
  • GGAL $2.09M · 1 buyGrupo Financiero Galicia S.A.
  • ENR $2.02M · 1 buyEnergizer Holdings, Inc.
  • ACI $1.96M · 1 buyAlbertsons Companies, Inc.
  • RH $1.83M · 1 buyRH
  • JCTC $1.61M · 2 buys, 2 insidersJewett-Cameron Trading Co. Ltd.
  • FULC $1.48M · 2 buys, 2 insidersFulcrum Therapeutics, Inc.
  • BOLD $1.25M · 3 buys, 2 insidersBoundless Bio, Inc.
  • CRDF $1.00M · 1 buyCardiff Oncology Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.